Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 15/20 | 0.65 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimelautide SCHEMBL28126753 | 1.00 | NOD1 (0.65) | NOD1SLC6A5ESR1PGRHTR1A | |
| SCHEMBL10653624 | 0.92 | ESR1 (0.57) | NOD1SLC6A5ESR1PGRHTR1A | |
| Tabilautide SCHEMBL446062 | 0.88 | NOD1 (0.72) | NOD1SLC6A5ESR1PGRHTR1A | |
| Tabilautide SCHEMBL29711463 | 0.88 | NOD1 (0.72) | NOD1SLC6A5ESR1PGRHTR1A | |
| SCHEMBL9785097 | 0.84 | NOD1 (0.71) | NOD1SLC6A5FAAH | |
| SCHEMBL11283421 | 0.84 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL29429263 | 0.84 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL29675028 | 0.84 | NOD1 (0.62) | NOD1SLC6A5FAAH | |
| SCHEMBL10419869 | 0.84 | PLA2G2C (0.55) | NOD1SLC6A5FAAHTLR2 | |
| SCHEMBL29429265 | 0.84 | NOD1 (0.62) | NOD1SLC6A5FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106540237-A | A kind of pharmaceutical composition for suppressing gastric cancer | 徐州诺克非医药科技有限公司 | 2017-03-29 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-7476386-B1 | Mixed lipopeptide micelles for inducing an immune response | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-01-13 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| EP-1035866-B1 | MIXED LIPOPEPTIDE MICELLES FOR INDUCING AN IMMUNE RESPONSE AND THEIR THERAPEUTIC USES | INST NAT SANTE RECH MED (FR) | 2006-05-17 | — | — | EP | claimed |
| EP-1068226-B1 | LIPOPEPTIDES INDUCING T LYMPHOCYTIC CYTOTOXICITY BEARING AT LEAST ONE AUXILIARY T EPITOPE, AND USES FOR VACCINATION | INST NAT SANTE RECH MED (FR) | 2005-04-20 | — | — | EP | claimed |
| EP-1068226-A1 | LIPOPEPTIDES INDUCING T LYMPHOCYTIC CYTOTOXICITY BEARING AT LEAST ONE AUXILIARY T EPITOPE, AND USES FOR VACCINATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-01-17 | — | — | EP | claimed |
| EP-1035866-A2 | MIXED LIPOPEPTIDE MICELLES FOR INDUCING AN IMMUNE RESPONSE AND THEIR THERAPEUTIC USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2000-09-20 | — | — | EP | claimed |
| US-6015564-A | POLYPEPTIDES WITH FATTY ACID AND STEROIDS | INSTITUT PASTEUR DE LILLE (FR) | 2000-01-18 | — | — | US | claimed |
| US-5993823-A | BETWEEN 10 AND 40 AMINO ACIDS AND AT LEAST ONE ANTIGENIC DETERMINANT, ALSO COMPRISING A CHAIN FROM PIMELAUTIDE, TRIMEXAUTIDE, HEXADECANOIC ACID, 2-AMINO-HEXADECANOIC ACID, STEROID GROUPS AND DERIVATIVES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 1999-11-30 | — | — | US | claimed |
| WO-1999051630-A1 | LIPOPEPTIDES INDUCING T LYMPHOCYTIC CYTOTOXICITY BEARING AT LEAST ONE AUXILIARY T EPITOPE, AND USES FOR VACCINATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM (FR) | 1999-10-14 | — | — | WO | claimed |
| EP-0945461-A1 | Lipopeptides inducing T-cyxtotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 1999-09-29 | — | — | EP | claimed |
| WO-1999027954-A2 | MIXED LIPOPEPTIDE MICELLES FOR INDUCING AN IMMUNE RESPONSE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-06-10 | — | — | WO | claimed |
| US-5871746-A | FOR IMMUNIZING AGAINST PATHOGENIC AGENTS SUCH AS VIRUSES ORPARASITES; ONE OR MORE CHAINS DERIVED FROM FATTY ACIDS OR MODIFIED STEROID GROUPS | INSTITUT NATIONAL DE LA SAINTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-02-16 | — | — | US | claimed |
| EP-0491628-A2 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 1992-06-24 | — | — | EP | claimed |
| US-20230212243-A1 | Neoantigenic Epitopes Associated with SF3B1 Mutations | INSTITUT CURIE (FR) | 2023-07-06 | — | — | US | disclosed |
| EP-4149952-A1 | NEOANTIGENIC EPITOPES ASSOCIATED WITH SF3B1 MUTATIONS | Institut Curie (FR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2021228999-A1 | NEOANTIGENIC EPITOPES ASSOCIATED WITH SF3B1 MUTATIONS | INSTITUT CURIE (FR) | 2021-11-18 | — | — | WO | disclosed |
| EP-3860649-A1 | METHOD FOR TREATING A HUMAN IMMUNODEFICIENCY VIRUS INFECTION | UNIVERSITE DE BORDEAUX (FR) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020245433-A1 | MIXTURES OF IMMUNOGENIC CD8 T EPITOPES OF THE EBOLA VIRUS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020144355-A2 | IMMUNOGENIC PEPTIDES DERIVED FROM THE NUCLEOPROTEIN OF THE EBOLA ZAIRE VIRUS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020127996-A2 | MIXTURES OF CYCLIN B1 IMMUNOGENIC CD8+ T EPITOPES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020070427-A1 | METHOD FOR TREATING A HUMAN IMMUNODEFICIENCY VIRUS INFECTION | Universite de Bordeaux (FR) | 2020-04-09 | — | — | WO | disclosed |
| EP-3016974-B1 | IMMUNOGENIC PEPTIDES FROM TUMORAL ANTIGEN CYCLIN B1. | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2020-03-11 | — | — | EP | disclosed |
| US-10550166-B2 | Immunogenic peptides of the cyclin B1 tumor antigen | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-02-04 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180086804-A1 | Immunogenic Peptides of the Cyclin B1 Tumor Antigen | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-03-29 | — | — | US | disclosed |
| US-9687539-B2 | CD4+ T survivin epitopes and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2017-06-27 | — | — | US | disclosed |
| CN-106540237-A | A kind of pharmaceutical composition for suppressing gastric cancer | 徐州诺克非医药科技有限公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-106540237-A | A kind of pharmaceutical composition for suppressing gastric cancer | 徐州诺克非医药科技有限公司 | 2017-03-29 | — | — | CN | disclosed |
| US-20160257727-A1 | IMMUNOGENIC PEPTIDES OF THE CYCLIN B1 TUMOR ANTIGEN | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-09-08 | — | — | US | disclosed |
| EP-3016974-A1 | IMMUNOGENIC PEPTIDES OF THE CYCLIN B1 TUMOUR ANTIGEN | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2016-05-11 | — | — | EP | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20150050304-A1 | CD4+ T Survivin Epitopes and Uses Thereof | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2015-02-19 | — | — | US | disclosed |
| WO-2015001526-A1 | IMMUNOGENIC PEPTIDES OF THE CYCLIN B1 TUMOUR ANTIGEN | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-01-08 | — | — | WO | disclosed |
| CN-101693672-B | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2014-11-12 | — | — | CN | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-1931377-B1 | CD4+ T SURVIVIN EPITOPES AND USES THEREOF | COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-07-02 | — | — | EP | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20130344476-A1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-26 | — | — | US | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| CN-103232381-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2013-08-07 | — | — | CN | disclosed |
| US-8501450-B2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-1951748-B1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMA (US) | 2013-07-24 | — | — | EP | disclosed |
| CN-1869061-B | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2013-04-24 | — | — | CN | disclosed |
| CN-101633636-B | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2013-03-13 | — | — | CN | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1678202-B1 | HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS | VERTEX PHARMA (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1320540-B9 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMA (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2392590-A2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392589-A2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392588-A2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2374464-A2 | HCV N3S-NS4A protease inhibition | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110244549-A1 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2371839-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2368901-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368877-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368878-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| CN-102160891-A | Hcv ns3-ns4a protease inhibition | VERTEX PHARMA | 2011-08-24 | — | — | CN | disclosed |
| CN-102123731-A | Immunogenic peptides derived from the midkine protein, as an anticancer vaccine | COMMISSARIAT ENERGIE ATOMIQUE | 2011-07-13 | — | — | CN | disclosed |
| US-20110159022-A1 | Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2011-06-30 | — | — | US | disclosed |
| US-20110086006-A1 | HCV NS3-NS4 Protease Resistance Mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-14 | — | — | US | disclosed |
| EP-2296697-A1 | IMMUNOGENIC PEPTIDES DERIVED FROM THE MIDKINE PROTEIN, AS AN ANTICANCER VACCINE | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2011-03-23 | — | — | EP | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| US-20110059886-A1 | HCV NS3-NS4A Protease Inhibition | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7884199-B2 | computer aided drug design; pharmacogenetics around telaprevir resistance; hepatitis C virus (HCV) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100324829-A1 | METHOD OF SELECTING HLA-DP4 LIGANDS AND THE APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-12-23 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1878720-B1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2010-10-06 | — | — | EP | disclosed |
| US-7803378-B2 | Antigen imitating extracellular areas of membrane proteins of type III produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 2010-09-28 | — | — | US | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100203080-A1 | Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof | COMMISSARIAT A I'ENERGIE ATOMIQUE (FR) | 2010-08-12 | — | — | US | disclosed |
| CN-1894276-B | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMA | 2010-06-16 | — | — | CN | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-7718575-B2 | Method of selecting HLA-DP4 ligands and the applications thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7705138-B2 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| CN-101696232-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2010-04-21 | — | — | CN | disclosed |
| CN-101693672-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2010-04-14 | — | — | CN | disclosed |
| WO-2010024870-A1 | SKIN-CONTACTING-ADHESIVE FREE DRESSING | JENNINGS-SPRING BARBARA BROOKE (US) | 2010-03-04 | — | — | WO | disclosed |
| CN-101633636-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2010-01-27 | — | — | CN | disclosed |
| EP-1861418-B1 | T CD4+ EPITOPES OF TYPE I AND II LATENCY ANTIGENS OF THE EPSTEIN-BARR VIRUS, WHICH CAN BE RECOGNISED BY THE MAJORITY OF INDIVIDUALS IN THE CAUCASIAN POPULATION AND APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009153463-A1 | IMMUNOGENIC PEPTIDES DERIVED FROM THE MIDKINE PROTEIN, AS AN ANTICANCER VACCINE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-12-23 | — | — | WO | disclosed |
| US-7612093-B2 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITED THERAPEUTICS CORPORATION (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101516389-A | Combination therapy for the treatment of viral infections | UNITED THERAPEUTICS CORP (US) | 2009-08-26 | — | — | CN | disclosed |
| CN-100522991-C | Peptidomimetic protease inhibitors | LILLY CO ELI (US) | 2009-08-05 | — | — | CN | disclosed |
| US-20090191555-A1 | HCV NS3-NS4 Protease Resistance Mutants | VERTEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1804821-A4 | HCV NS3-NS4A PROTEASE INHIBITION | VERTEX PHARMA (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090130134-A1 | T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2009-05-21 | — | — | US | disclosed |
| EP-1320540-B1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMA (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2054076-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | United Therapeutics Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| CN-101405295-A | Hepatitis C virus variants | VERTEX PHARMA (US) | 2009-04-08 | — | — | CN | disclosed |
| WO-2009040674-A2 | A PUBLIC AND IMMUNOGENIC CD4+ T CELL EPITOPE OF THE HIV TAT PROTEIN AND ITS APPLICATIONS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-04-02 | — | — | WO | disclosed |
| EP-2042600-A1 | A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7494660-B2 | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-7488791-B2 | Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-02-10 | — | — | US | disclosed |
| US-7476386-B1 | Mixed lipopeptide micelles for inducing an immune response | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-01-13 | — | — | US | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| US-20090004214-A1 | Cd4+ Survivin Epitopes and Uses Thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2009-01-01 | — | — | US | disclosed |
| US-20080267915-A1 | Hcv Ns3-Ns4a Protease Inhibition | VERTEX PHARMACEUTICALS (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1958956-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951748-A2 | HEPATITIS C VIRUS VARIANTS | Vertex Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1658846-B1 | N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol for treating hepatitis virus infections | UNITED THERAPEUTICS CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1931377-A1 | CD4+ T SURVIVIN EPITOPES AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-06-18 | — | — | EP | disclosed |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | UNITED THERAPEUTICS CORPORATION | 2008-06-05 | — | — | US | disclosed |
| WO-2008063727-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
| CN-100382804-C | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections | SEARLE & CO (US) | 2008-04-23 | — | — | CN | disclosed |
| US-20080075717-A1 | Antigen Imitating Extracellular Areas of Membrane Proteins of Type III Produced from Intracellular Pathogenic Micro-Organisms, Derived Conformational Antibodies and the Use Thereof | UNIVERSITE DE LILLE 2 (FR) | 2008-03-27 | — | — | US | disclosed |
| EP-1527089-B1 | MIXTURE OF PEPTIDES FROM C AND NS3 PROTEINS OF THE HEPATITIS C VIRUS AND APPLICATIONS THEREOF | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2008-03-26 | — | — | EP | disclosed |
| CN-100364534-C | Use of n-substituted-1,5-di deoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | SEARLE & CO (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1876173-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1861418-A2 | T CD4+ EPITOPES OF TYPE I AND II LATENCY ANTIGENS OF THE EPSTEIN-BARR VIRUS, WHICH CAN BE RECOGNISED BY THE MAJORITY OF INDIVIDUALS IN THE CAUCASIAN POPULATION AND APPLICATIONS THEREOF | Centre National de la Recherche Scientifique (FR) | 2007-12-05 | — | — | EP | disclosed |
| CN-101072575-A | HCV NS 3-NS 4A protease inhibition | VERTEX PHARMA (US) | 2007-11-14 | — | — | CN | disclosed |
| EP-1849797-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070231262-A1 | Hepatitis C virus variants | VERTEX PHARMACEUTICALS, INCORPORATED | 2007-10-04 | — | — | US | disclosed |
| WO-2007059221-A9 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMA (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-1804821-A2 | HCV NS3-NS4A PROTEASE INHIBITION | Vertex Pharmaceuticals, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| WO-2007059221-A2 | HEPATITIS C VIRUS VARIANTS | VERTEX PHARMACEUTICALS, INC (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007036638-A1 | CD4+ T SURVIVIN EPITOPES AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007026078-A2 | T CD4+ EPITOPES OF MAGE-A ANTIGENS RESTRICTED TO HLA-DP4 AND THE USE THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-03-08 | — | — | WO | disclosed |
| EP-1061922-B9 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | UNITED THERAPEUTICS CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| CN-1894276-A | HCV NS3-NS4A protease resistance mutants | VERTEX PHARMA (US) | 2007-01-10 | — | — | CN | disclosed |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | UNITED THERAPEUTICS CORPORATION | 2006-11-23 | — | — | US | disclosed |
| EP-1714676-A2 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. Searle LLC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006082313-A2 | T CD4+ EPITOPES OF TYPE I AND II LATENCY ANTIGENS OF THE EPSTEIN-BARR VIRUS, WHICH CAN BE RECOGNISED BY THE MAJORITY OF INDIVIDUALS IN THE CAUCASIAN POPULATION AND APPLICATIONS THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-10 | — | — | WO | disclosed |
| EP-1678202-A1 | HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS | Vertex Pharmaceuticals Incorporated (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1061922-B1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | SEARLE LLC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060110401-A1 | Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2006-05-25 | — | — | US | disclosed |
| EP-1658846-A1 | Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. SEARLE & CO. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | disclosed |
| EP-1035866-B1 | MIXED LIPOPEPTIDE MICELLES FOR INDUCING AN IMMUNE RESPONSE AND THEIR THERAPEUTIC USES | INST NAT SANTE RECH MED (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-20060094671-A1 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | UNITHER VIROLOGY, LLC | 2006-05-04 | — | — | US | disclosed |
| WO-2006039488-A2 | HCV NS3-NS4A PROTEASE INHIBITION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006027468-A2 | HLA-DP4 RESTRICTED T CD4+ DU VIH EPITOPES AND THE USE THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2006-03-16 | — | — | WO | disclosed |
| US-20050267153-A1 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | MUELLER RICHARD A | 2005-12-01 | — | — | US | disclosed |
| EP-1587825-A2 | ANTIGEN IMITATING EXTRACELLULAR AREAS OF MEMBRANE PROTEINS OF TYPE III PRODUCED FROM INTRACELLULAR PATHOGENIC MICRO-ORGANISMS, DERIVED CONFORMATIONAL ANTIBODIES AND THE USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-10-26 | — | — | EP | disclosed |
| CN-1679568-A | Use of n-substituted-1,5-di deoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | SEARLE & CO (US) | 2005-10-12 | — | — | CN | disclosed |
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| US-20050136400-A1 | NS3-NS4A protease resistance mutants | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | PHARMACIA CORPORATION | 2005-06-02 | — | — | US | disclosed |
| CN-1202824-C | Use of N-substituted 1, 5-dideoxy-1, 5-imino-D-glucitol compounds for the treatment of hepatitis virus infections | SEARLE & CO (US) | 2005-05-25 | — | — | CN | disclosed |
| WO-2005042570-A1 | HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1527089-A2 | MIXTURE OF PEPTIDES FROM C AND NS3 PROTEINS OF THE HEPATITIS C VIRUS AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2005-05-04 | — | — | EP | disclosed |
| EP-1068226-B1 | LIPOPEPTIDES INDUCING T LYMPHOCYTIC CYTOTOXICITY BEARING AT LEAST ONE AUXILIARY T EPITOPE, AND USES FOR VACCINATION | INST NAT SANTE RECH MED (FR) | 2005-04-20 | — | — | EP | disclosed |
| US-20050059107-A1 | Method of selecting hla-dp4 ligands and the applications thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6809083-B1 | INHIBITING REPLICATION AND SECRETION; REDUCED TOXICITY | UNITHER VIROLOGY, LLC | 2004-10-26 | — | — | US | disclosed |
| EP-1453853-A2 | MIXTURE OF PEPTIDES ORIGINATING FROM A NEF PROTEIN AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-09-08 | — | — | EP | disclosed |
| US-20040170644-A1 | Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-09-02 | — | — | US | disclosed |
| WO-2004069140-A2 | ANTIGEN IMITATING EXTRACELLULAR AREAS OF MEMBRANE PROTEINS OF TYPE III PRODUCED FROM INTRACELLULAR PATHOGENIC MICRO-ORGANISMS, DERIVED CONFORMATIONAL ANTIBODIES AND THE USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2004-08-19 | — | — | WO | disclosed |
| EP-1436626-A2 | METHOD FOR SELECTING HLA-DP4 LIGANDS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-07-14 | — | — | EP | disclosed |
| US-20040115622-A1 | Mixture of peptides originating from a Nef protein and applications thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-06-17 | — | — | US | disclosed |
| US-6747149-B2 | ADMINISTERING VIRICIDES SUCH AS N-NONENYL GLUCOSAMINE, AND OPTIONALLY WITH MIXTURES OF NUCLEOSIDES, NUCLEOTIDES, IMMUNOMODULATORS OR IMMUNOSTIMULANTS FOR PROPHYLAXIS VIRAL DISEASES | G. D. SEARLE & CO. | 2004-06-08 | — | — | US | disclosed |
| WO-2004014936-A2 | MIXTURE OF PEPTIDES FROM C AND NS3 PROTEINS OF THE HEPATITIS C VIRUS AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-02-19 | — | — | WO | disclosed |
| JP-2004043501-A | CYTOTOTXIC T LYMPHOCYTE INDUCED LIPOPEPTIDE AND VACCINE | INST PASTEUR DE LILLE | 2004-02-12 | — | — | JP | disclosed |
| US-6689759-B1 | COMBINED WITH NUCLEOSIDE AND/OR NUCLEOTIDE ANTIVIRAL AGENTS AND IMMUNOSTIMULANTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
| EP-1383535-A2 | MIXTURE OF PEPTIDES DERIVED FROM E6 AND/OR E7 PAPILLOMAVIRUS PROTEINS AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-01-28 | — | — | EP | disclosed |
| CN-1451014-A | Peptidomimetic protease inhibitors | LILLY CO ELI (US) | 2003-10-22 | — | — | CN | disclosed |
| EP-1320540-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2003040299-A2 | METHOD OF SELECTING HLA-DP4 LIGANDS AND THE APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2003-05-15 | — | — | WO | disclosed |
| US-6545021-B1 | Including ether and ester derivatives as well as N-carbonyl derivatives | G.D. SEARLE & CO. | 2003-04-08 | — | — | US | disclosed |
| WO-2003016572-A1 | OLIGONUCLEOTIDE THERAPEUTICS FOR TREATING HEPATITIS C VIRUS INFECTIONS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| CN-1094943-C | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID CO (US) | 2002-11-27 | — | — | CN | disclosed |
| WO-2002090382-A2 | MIXTURE OF PEPTIDES DERIVED FROM E6 AND/OR E7 PAPILLOMAVIRUS PROTEINS AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002062834-A2 | MIXTURE OF PEPTIDES ORIGINATING FROM A NEF PROTEIN AND APPLICATIONS THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002018369-A2 | PEPTIDOMIMETIC PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| CN-1328457-A | Use of N-substituted 1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | SEARLE & CO (US) | 2001-12-26 | — | — | CN | disclosed |
| EP-1084253-A1 | HIV VIRUS MIMOTOPES | Aventis Pasteur (FR) | 2001-03-21 | — | — | EP | disclosed |
| EP-1068226-A1 | LIPOPEPTIDES INDUCING T LYMPHOCYTIC CYTOTOXICITY BEARING AT LEAST ONE AUXILIARY T EPITOPE, AND USES FOR VACCINATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-01-17 | — | — | EP | disclosed |
| EP-1065212-A2 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 2001-01-03 | — | — | EP | disclosed |
| EP-1035866-A2 | MIXED LIPOPEPTIDE MICELLES FOR INDUCING AN IMMUNE RESPONSE AND THEIR THERAPEUTIC USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2000-09-20 | — | — | EP | disclosed |
| US-6015564-A | POLYPEPTIDES WITH FATTY ACID AND STEROIDS | INSTITUT PASTEUR DE LILLE (FR) | 2000-01-18 | — | — | US | disclosed |
| WO-1999066046-A1 | HIV VIRUS MIMOTOPES | AVENTIS PASTEUR (FR) | 1999-12-23 | — | — | WO | disclosed |
| US-5993823-A | BETWEEN 10 AND 40 AMINO ACIDS AND AT LEAST ONE ANTIGENIC DETERMINANT, ALSO COMPRISING A CHAIN FROM PIMELAUTIDE, TRIMEXAUTIDE, HEXADECANOIC ACID, 2-AMINO-HEXADECANOIC ACID, STEROID GROUPS AND DERIVATIVES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 1999-11-30 | — | — | US | disclosed |
| WO-1999058561-A1 | HEPATITIS C VIRUS MIMOTOPES | PASTEUR MERIEUX SERUMS & VACCINS (FR) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999051630-A1 | LIPOPEPTIDES INDUCING T LYMPHOCYTIC CYTOTOXICITY BEARING AT LEAST ONE AUXILIARY T EPITOPE, AND USES FOR VACCINATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM (FR) | 1999-10-14 | — | — | WO | disclosed |
| EP-0491628-B1 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | PASTEUR INSTITUT (FR) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945461-A1 | Lipopeptides inducing T-cyxtotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945461-A1 | Lipopeptides inducing T-cyxtotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999027954-A2 | MIXED LIPOPEPTIDE MICELLES FOR INDUCING AN IMMUNE RESPONSE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-06-10 | — | — | WO | disclosed |
| US-5871746-A | FOR IMMUNIZING AGAINST PATHOGENIC AGENTS SUCH AS VIRUSES ORPARASITES; ONE OR MORE CHAINS DERIVED FROM FATTY ACIDS OR MODIFIED STEROID GROUPS | INSTITUT NATIONAL DE LA SAINTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-02-16 | — | — | US | disclosed |
| US-5658945-A | ANTICANCER AGENT; AIDS THERAPY; CONTROLLING INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5633280-A | ACCELERATED RECOVERY FROM CHEMOTHERAPY, RADIATION TREATMENT, BONE MARROW TRANSPLANTATION, INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5616612-A | THERAPY FOR CANCER, AIDS, ANEMIA, INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-04-01 | — | — | US | disclosed |
| US-5602275-A | MAY BE USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO- OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
| EP-0652228-B1 | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID CO (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5545662-A | USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION, OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0652228-A1 | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| CN-1100413-A | Urethanes and ureas that induce cytokine production | AMERICAN CYANAMID CO (US) | 1995-03-22 | — | — | CN | disclosed |
| US-5312831-A | Immunology, anticarcinogenic agents and AIDS treatment | AMERICAN CYANAMID COMPANY (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0491628-A2 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 1992-06-24 | — | — | EP | disclosed |
| EP-0491628-A2 | Lipopeptide inducing T-cytotoxic lymphocytes and their use as vaccines | INSTITUT PASTEUR DE LILLE (FR) | 1992-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197299-A1 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | CTRC, PEPD, CTSC | NOD1 721/4885SLC6A5 4009/4885ESR1 2827/4885 |
| US-20110086006-A1 | HCV NS3-NS4 Protease Resistance Mutants | ATG4A, CUL4A, TMPRSS4 | NOD1 1789/4885SLC6A5 1804/4885ESR1 3149/4885 |
| US-20060094671-A1 | Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy | HAVCR2, DERA, GALE | NOD1 60/4885SLC6A5 1283/4885ESR1 4563/4885 |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | GBA3, EIF2AK2, GAA | NOD1 2381/4885SLC6A5 3090/4885ESR1 4462/4885 |
| US-20160257727-A1 | IMMUNOGENIC PEPTIDES OF THE CYCLIN B1 TUMOR ANTIGEN | CCNB1, CCNB3, CCNB2 | NOD1 3171/4885SLC6A5 4837/4885ESR1 1815/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | NOD1 187/4885SLC6A5 3947/4885ESR1 2526/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | NOD1 187/4885SLC6A5 3947/4885ESR1 2526/4885 |
| US-20090191555-A1 | HCV NS3-NS4 Protease Resistance Mutants | ATG4A, CUL4A, TMPRSS4 | NOD1 1789/4885SLC6A5 1804/4885ESR1 3149/4885 |
| US-20110059886-A1 | HCV NS3-NS4A Protease Inhibition | SERPINB1, ERAP1, PREP | NOD1 587/4885SLC6A5 3638/4885ESR1 2572/4885 |
| US-20060264468-A1 | Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections | IMPDH1, HAVCR2, DERA | NOD1 92/4885SLC6A5 2212/4885ESR1 4724/4885 |
| US-20080267915-A1 | Hcv Ns3-Ns4a Protease Inhibition | SERPINB1, ERAP1, PREP | NOD1 587/4885SLC6A5 3638/4885ESR1 2572/4885 |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | NOD1 73/4885SLC6A5 1800/4885ESR1 4578/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | NOD1 187/4885SLC6A5 3947/4885ESR1 2526/4885 |
| US-20050136400-A1 | NS3-NS4A protease resistance mutants | ATG4A, CUL4A, DPP4 | NOD1 1974/4885SLC6A5 2143/4885ESR1 2711/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | NOD1 272/4885SLC6A5 3810/4885ESR1 3130/4885 |
| US-20050267153-A1 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | NOD1 73/4885SLC6A5 1800/4885ESR1 4578/4885 |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | EIF2AK2, ZC3HAV1, HAVCR2 | NOD1 2002/4885SLC6A5 3511/4885ESR1 4063/4885 |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | HAVCR2, DERA, UGGT1 | NOD1 53/4885SLC6A5 1101/4885ESR1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.